A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Latest Information Update: 25 Nov 2024
At a glance
- Drugs NOUS-209 (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Nouscom
Most Recent Events
- 20 Nov 2024 Planned End Date changed from 15 Jul 2026 to 30 Nov 2026.
- 20 Nov 2024 Planned primary completion date changed from 15 Mar 2025 to 30 Apr 2025.
- 19 Nov 2024 Status changed from recruiting to active, no longer recruiting.